Previous 10 | Next 10 |
2023-05-12 17:00:00 ET Citius Pharmaceuticals press release ( NASDAQ: CTXR ): Q2 GAAP EPS of -$0.07 misses by $0.02 . Cash and cash equivalents of $29.1 million as of March 31, 2023; $15 million in gross proceeds from equity financing as of May 8, 202. For furthe...
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2023 Financial Results and Provides Business Update PR Newswire $29.1 million in cash and cash equivalents as of March 31, 2023 ; $15 million registered direct offering in May 2023 extends runway throug...
Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering PR Newswire CRANFORD, N.J. , May 8, 2023 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to...
2023-05-04 10:14:51 ET Citius Pharmaceuticals ( NASDAQ: CTXR ) down 16% entered purchase agreement for an aggregate of 12.5M shares and warrants at a purchase price of $1.20 per share. The closing of the offering is expected to occur on or about May 8, 2023. Gross ...
2023-05-04 08:55:15 ET Enviva EVA -50% after Q1 earning release . First Horizon Corporation FHN -43% after merger with TD Bank ends. Sensus Healthcare SRTS -42% after Q1 earning release . PacWest Bancorp PACW -41% on confirming sale talks follow...
Citius Pharmaceuticals Announces $15 Million Registered Direct Offering PR Newswire CRANFORD, N.J. , May 4, 2023 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the develo...
2023-04-24 11:58:12 ET Citius Pharmaceuticals ( NASDAQ: CTXR ) is down 8% in late Monday moring trading despite reporting that it is near completion of a phase 3 trial for its Mino-Lok system. Mino-Lok is an antibiotic lock solution to salvage catheters in patients wit...
Citius Pharmaceuticals Advances Mino-Lok® Phase 3 Trial Achieving 85 of 92 Events to Date PR Newswire CRANFORD, N.J. , April 24, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical comp...
2023-04-19 12:49:23 ET Gainers: SAI.TECH Global Corporation ( SAI ) +48% . Bed Bath & Beyond ( BBBY ) +40% . VYNE Therapeutics ( VYNE ) +34% . Boqii Holding Limited ( BQ ) +30% . CXApp ( CXAI ) +19% . Western Alliance Ban...
Citius Pharmaceuticals Completes Enrollment in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids PR Newswire Topline Results anticipated by the end of Q2 2023 CRANFORD, N.J. , April 3, 2023 /PRNewswire/ -- Citius Pharmaceuticals, I...
News, Short Squeeze, Breakout and More Instantly...
Citius Pharmaceuticals Inc. Company Name:
CTXR Stock Symbol:
NASDAQ Market:
Citius Pharmaceuticals Inc. Website:
2024-07-18 10:20:00 ET July 18, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmaceutical compa...
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 18, 2024) - Investorideas.com , a go-to investing platform releases the second of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a late-stage biopharmaceutical c...
2024-07-17 10:10:00 ET July 17, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmaceutical compan...